On January 7, 2019, PEAR Therapeutics and Sandoz announced the commercial launch of reSET-OT, a mobile medical digital therapeutic application to treat opioid use disorder (OUD). reSET-O, which is available immediately, was developed by PEAR Therapeutics and is being commercialized by Sandoz. The reSET-O application is a 12-week prescription digital therapeutic (PDT) that provides adjunctive cognitive behavioral therapy (CBT) for adults with OUD enrolled in outpatient treatment and being treated with transmucosal buprenorphine. The application also includes a contingency management program, which is a behavior modification intervention. Use is limited to persons with a valid prescription . . .